DrugDashboards

Xylocaine MPF

Lidocaine Hydrochloride · LIDOCAINE HYDROCHLORIDE ANHYDROUS 10 mg/mL · Injection, Solution · Epidural; Infiltration; Intracaudal; Perineural · Fresenius Kabi USA, LLC

NDC 63323-0492-37 · 25 VIAL, SINGLE-DOSE in 1 TRAY / 30 mL in 1 VIAL, SINGLE-DOSE · NDA · View full market →

The short version

14 companies list this market (plus 8 repackagers, which add no supply) — deep enough that no single failure threatens the supply. FDA lists this drug as in shortage right now (40 presentations or makers) — reason given: “demand increase for the drug”. 2 Class II recalls hit this product in the past year (Fresenius Kabi USA, LLC).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

ⓘ How this was built
Data sources
  • FDA NDC Directory (openFDA) — labelers active in the last 30 days, repackagers classified from DailyMed SPL establishment roles
  • CMS NADAC — latest price vs the price in effect ~12 months earlier
  • FDA drug shortages and enforcement reports (openFDA)
  • FDA inspection classifications; DrugDashboards fragility score and 90-day shortage model
Method

Each sentence is a template that fires only when its condition holds in the data shown lower on this page: maker counts are distinct FDA labelers listing this molecule and dosage form in the last 30 days minus classified repackagers; the price trend compares the newest NADAC with the last price in effect at least 9 months earlier; shortage and recall sentences restate FDA rows for this drug's presentations (Class I/II, trailing 12 months); the plant sentence needs a MANUFACTURE-role establishment with a drug-quality OAI in 24 months; the verdict restates the fragility band; the risk sentence appears only when the model's probability is at least 1.5× the typical market. Nothing here is inferred beyond those rules.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC weekly file (pharmacy acquisition, per unit)
  • CMS Part B ASP quarterly payment limit file + NDC–HCPCS crosswalk
  • CMS Maximum Fair Prices (IRA negotiated), matched on the NDC-9
  • CMS Part D Spending by Drug (annual, name-matched, gross incl. dispensing fee)
  • CMS Part D plan formulary/pricing files (SPUF): point-of-sale price across plans
  • VA FSS / Big4 federal contract prices (per package; per unit when the package is a count above 1)
  • CMS Federal Upper Limits + weighted AMP for the multiple-source drug group (monthly)
  • Texas DSHS annual WAC catalog, then Texas/California increase filings (per package)
Method

Each rung is the newest figure for this NDC from one price system, shown with its own unit — units differ, so compare a rung over time, not rung against rung. Part B is the file's payment limit (typically ASP+6%, WAC+3% for new drugs; sequestration is applied at claim level); when the NDC maps to several HCPCS codes the lowest code is shown and the count noted. Part D average is shown only on an exact brand-name match or a generic name with a single CMS row. FSS keeps the lowest active contract price, Big4 first, and skips 1¢ placeholders. The FUL belongs to the whole multiple-source group, so a brand NDC shows its generic group's ceiling. WAC is the Texas catalog's current list price, else the newest increase filing already in effect. To check a rung: open the named CMS/VA/state file for the date shown and find this NDC.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Federal ceiling (Big4)$68.29per package of 25X30MLFresenius Kabi, LLC · Jan 1, 2026
  • List price (WAC, as filed)$294.75per packageTexas DSHS annual report · Fresenius Kabi USA · 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

ⓘ How this was built
Data sources
  • CMS NADAC weekly files (data.medicaid.gov), December 2024 onward
  • CMS NADAC per-year archive files, 2013 – November 2024, averaged per month
  • CMS Federal Upper Limit file — weighted average manufacturer price (WAMP) of the generic group (dashed line)
Method

One line, two regimes: before December 2024 each point is the average of that month's archived NADAC rows for this NDC; from December 2024 each point is a row from the weekly file, which CMS publishes only when the price changes, so the line holds flat until the next change and is extended to today when the last row is under 6 months old. Since the December 2024 file CMS computes generic NADAC as a 3-month moving average, so recent generic moves are smoothed and lag the market. The dashed WAMP is the manufacturer-side average for the whole multiple-source group, not this NDC alone. To check a point: open the NADAC file for that date on data.medicaid.gov and find this NDC.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$294.75
Reported to Texas DSHS · 2026 annual filing · Fresenius Kabi USA · package: 25 VIAL, SINGLE-DOSE in 1 TRAY / 30 mL in 1 VIAL, SINGLE-DOSE

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

ⓘ How this was built
Data sources
  • CMS State Drug Utilization Data (SDUD), data.medicaid.gov
Method

CMS's Medicaid Amount Reimbursed for this exact NDC, summed across every state and quarter of the period shown, fee-for-service and managed care together — the program's gross payment to pharmacies before manufacturer rebates (statutory rebates alone recover 23.1% or more of a brand's price). Cells CMS suppresses (fewer than 11 prescriptions in a state-quarter) are absent from the file, so totals for small drugs run low. The prescription count is CMS's Number of Prescriptions. To check: filter the SDUD file for the year to this NDC and sum the column.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

$24,732
3,321 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NDCs that have a NADAC price and a generic name.

90-day shortage risk (model v2)

0.6%chance of a new FDA shortage posting for lidocaine hydrochloride (injectable) in the next 90 days

sterile injectable · 4 Class I/II recall(s) in 12 months · OAI inspection at a producing facility (24 months)

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

ⓘ How this was built
Data sources
  • FDA NDC Directory labeler counts, CMS NADAC price trend, openFDA shortages and enforcement, FDA inspection classifications, Wayback archive of FDA's shortage list (labels)
Method

A logistic regression over molecule × dosage-form markets, trained on a monthly grid of historical dates since 2019 with labels equal to whether a new FDA shortage posting appeared within the following 90 days; eight features knowable on each date (labeler count, sole-source flag, NADAC year-over-year change, Class I/II recalls, injectable form, discontinuation filings, open shortage episodes, recent OAI inspection). The probability shown is the model's output for today's feature values; the reasons are the features pushing this market's probability up, listed only when the feature actually holds here. Held-out performance and coefficients are on the fragility page.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Where it's made

Establishments this product's FDA label declares, with the role the label gives each (manufacture, API manufacture, pack, label, repack, analysis), located via FDA registration data. How we built this →

ⓘ How this was built
Data sources
  • DailyMed SPL labels (human prescription full release, monthly) — establishment DUNS and operations per label
  • FDA Drug Establishments Current Registration Site (DECRS) — DUNS to name and country
  • FDA Data Dashboard inspection classifications (Drug Quality Assurance)
Method

The label for this product's NDC-9 names each establishment and its operations; those DUNS numbers are matched to FDA's registration list for name and country. Only rows with a MANUFACTURE or API MANUFACTURE operation are places the drug is made; repack, relabel, pack, label and analysis rows are shown as what they are. The OAI badge means a drug-quality (GMP) inspection at that facility ended in Official Action Indicated within 24 months. Labels list plants, not volumes — a drug with two named plants may be made almost entirely at one. To check: open the label on DailyMed and its establishment section.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA006488
TE code
AP
Approval date
Jan 1, 1982
Patents / exclusivity
None on file
ⓘ How this was built
Data sources
  • FDA Orange Book data files — patent and exclusivity tables for application NDA006488, edition retrieved 2026-08-24
Method

Rows are the Orange Book's patent and exclusivity listings for this NDA, de-duplicated across product numbers (the file repeats a listing for every strength). A listed patent is a claim the sponsor filed; it may cover a use rather than the molecule, may be challenged, and may be delisted — a listing is not proof a generic is blocked. Pediatric extensions appear as *PED rows. FDA blocks automated downloads of the Orange Book from cloud servers, so the edition can trail FDA's monthly release; the retrieval date above is the edition shown. To check: search the application number on FDA's Orange Book site.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Shortage history

ⓘ How this was built
Data sources
  • FDA drug shortages via openFDA (current file: Current, To Be Discontinued, and recently Resolved rows)
  • Internet Archive (Wayback) snapshots of FDA's shortage list since 2019, reconstructed into episodes
  • DrugDashboards Kaplan–Meier duration curves and conditional duration model
Method

Top rows are FDA's live listings whose package NDC is this product or another package of the same generic name and dosage form. openFDA drops resolved rows after about six months, so older episodes come from monthly Wayback snapshots of FDA's file, matched on the molecule with dosage-form words stripped (that matching can pull in other salts or forms of the same molecule — the presentation is shown so you can tell). 'Month N of a typical M' compares this episode's age with the Kaplan–Meier median for its form class (injectable, oral solid, other) over episodes since October 2019, open episodes censored; the resolution odds come from a model conditioned on the episode's age and reason. To check: FDA's drug shortage database, and web.archive.org for its history.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • In shortage now — Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)Jun 13, 2018
    month 99 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)Jun 13, 2018
    Demand increase for the drug
    month 99 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)Jun 13, 2018
    month 99 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)Jun 13, 2018
    month 99 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)Jun 13, 2018
    Demand increase for the drug
    month 99 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)Jun 13, 2018
    Demand increase for the drug
    month 99 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)Jun 13, 2018
    Demand increase for the drug
    month 99 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)Jun 13, 2018
    month 99 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)Jun 13, 2018
    month 99 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)Feb 20, 2018
    Demand increase for the drug
    month 103 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)Oct 25, 2017
    month 107 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)Oct 25, 2017
    month 107 — 5× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)Oct 14, 2016
    month 119 — 6× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)Oct 14, 2016
    month 119 — 6× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)Feb 22, 2012
    Other
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)Feb 22, 2012
    Demand increase for the drug
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)Feb 22, 2012
    Demand increase for the drug
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-10)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-50)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 20 mg/2 mL (NDC 83634-653-02)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)Feb 22, 2012
    month 175 — 9× the typical 20-month injectable shortage · model puts 25% odds the market's longest-running episode resolves within 6 months
Archived episodes (FDA list history via Wayback, 2019+)
  • Planned discontinuation — Hospira, Inc., a Pfizer Company, Lidocaine Hydrochloride, Injection, 2%, USP (For Cardiac Use Only) 100 mg/5 mL (20 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4903-34)" (listed as “Lidocaine Hydrochloride Injection”)Nov 7, 2025 → last seen Jul 20, 2026
  • Planned discontinuation — Hospira, Inc., a Pfizer Company, Lidocaine Hydrochloride, Injection, 1%, USP (For Cardiac Use Only) 50 mg/5 mL (10 mg/mL) LifeShield™ ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4904-34)" (listed as “Lidocaine Hydrochloride Injection”)Nov 7, 2025 → last seen Jul 20, 2026
  • In shortage now — Huons Co., Ltd. (South Korea), Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2) (listed as “Lidocaine Hydrochloride Injection”)Jul 14, 2018 → last seen Jul 20, 2026
  • In shortage now — Spectra Medical Devices, LLC, Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1) (listed as “Lidocaine Hydrochloride Injection”)Jun 14, 2018 → last seen Jul 20, 2026
  • In shortage now — Hikma Pharmaceuticals USA, Inc., Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10) (listed as “Lidocaine Hydrochloride Injection”)Jun 13, 2018 → last seen Jul 20, 2026
  • In shortage now — Hikma Pharmaceuticals USA, Inc., Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25) (listed as “Lidocaine Hydrochloride Injection”)Jun 13, 2018 → last seen Jul 20, 2026
  • In shortage now — Eugia US LLC, Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20) (listed as “Lidocaine Hydrochloride Injection”)Jun 13, 2018 → last seen Jul 20, 2026
  • In shortage now — Eugia US LLC, Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20) (listed as “Lidocaine Hydrochloride Injection”)Jun 13, 2018 → last seen Jul 20, 2026

Showing 8 of 30 archived episodes.

Recalls (this NDC)

ⓘ How this was built
Data sources
  • FDA drug enforcement reports via openFDA
Method

Enforcement reports whose product NDC list includes this exact package NDC, newest first, with FDA's classification (I = reasonable probability of serious harm, II = temporary or reversible harm, III = unlikely to cause harm) and the recall's current status. Reports for other packages of the same drug are not shown here; 275 of the last year's Class I/II reports carry no NDC at all and cannot be matched. To check: search the recall number on openFDA or FDA's enforcement reports.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Class II · OngoingJul 16, 2026
    Fresenius Kabi USA, LLC — Presence of Particulate Matter: Hair was found in products
  • Class II · OngoingJul 16, 2026
    Fresenius Kabi USA, LLC — Presence of Particulate Matter: Hair was found in products
  • Class II · TerminatedApr 13, 2022
    Mckesson Medical-Surgical Inc. Corporate Office — cGMP deviations: Temperature abuse
  • Class II · TerminatedApr 13, 2022
    Mckesson Medical-Surgical Inc. Corporate Office — cGMP deviations: Temperature abuse
  • Class II · TerminatedJun 25, 2021
    Fresenius Kabi USA LLC — Low out of specification results for epinephrine assay.

Labelers of Lidocaine Hydrochloride (Injection, Solution)

22 labelers active in the last 30 days, of which 8 are repackagers; 0not seen for 30+ days. Keyed on FDA's generic-name string — other salts or forms of the molecule are separate rosters.

ⓘ How this was built
Data sources
  • FDA NDC Directory (openFDA), read daily since 2026-07-15 — labeler_name per package
  • DailyMed SPL establishment roles + name patterns → derived.labeler_kinds (repackager / manufacturer / unknown)
Method

One row per labeler that lists any package with this exact generic-name string and dosage form; strengths are combined. 'First seen' is the first daily snapshot that contained the labeler here (2026-07-15 for everything present at the start), 'last seen' the most recent; a labeler counts as active when seen in the last 30 days. Repackagers and relabelers are flagged when their own labels show only repack/relabel operations or their name matches a known repackager, and are excluded from every 'makers' count on this page. Listing is not volume: a labeler with a listed NDC may ship little or nothing. To check: search the generic name in FDA's NDC Directory and list the labelers.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

LabelerStrengthsFirst seenLast seen
Anthea Pharma Private LimitedLIDOCAINE HYDROCHLORIDE 20 mg/mL; LIDOCAINE HYDROCHLORIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Asclemed USA, Inc.repackagerLIDOCAINE HYDROCHLORIDE 10 mg/mL; LIDOCAINE HYDROCHLORIDE 20 mg/mL; LIDOCAINE HYDROCHLORIDE ANHYDROUS 20 mg/mLJul 15, 2026Sep 3, 2026
Camber Pharmaceuticals, Inc.LIDOCAINE HYDROCHLORIDE ANHYDROUS 10 mg/mL; LIDOCAINE HYDROCHLORIDE ANHYDROUS 20 mg/mLJul 15, 2026Sep 3, 2026
Eugia US LLCLIDOCAINE HYDROCHLORIDE 10 mg/mL; LIDOCAINE HYDROCHLORIDE 20 mg/mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCLIDOCAINE HYDROCHLORIDE 20 mg/mL; LIDOCAINE HYDROCHLORIDE ANHYDROUS 10 mg/mL; LIDOCAINE HYDROCHLORIDE ANHYDROUS 20 mg/mL (+5 more)Jul 15, 2026Sep 3, 2026
Henry Schein, Inc.repackagerLIDOCAINE HYDROCHLORIDE 20 mg/mL; LIDOCAINE HYDROCHLORIDE ANHYDROUS 10 mg/mL; LIDOCAINE HYDROCHLORIDE 10 mg/mL (+2 more)Jul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.LIDOCAINE HYDROCHLORIDE 20 mg/mL; LIDOCAINE HYDROCHLORIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.LIDOCAINE HYDROCHLORIDE 10 mg/mL; LIDOCAINE HYDROCHLORIDE 20 mg/mL; LIDOCAINE HYDROCHLORIDE 5 mg/mL (+2 more)Jul 15, 2026Sep 3, 2026
Lifestar Pharma LLCLIDOCAINE HYDROCHLORIDE 10 mg/mL; LIDOCAINE HYDROCHLORIDE 20 mg/mLJul 15, 2026Sep 3, 2026
Medical Purchasing Solutions, LLCrepackagerLIDOCAINE HYDROCHLORIDE 10 mg/mL; LIDOCAINE HYDROCHLORIDE 20 mg/mL; LIDOCAINE HYDROCHLORIDE ANHYDROUS 20 mg/mLJul 15, 2026Sep 3, 2026
NorthStar RxLLCLIDOCAINE HYDROCHLORIDE 20 mg/mL; LIDOCAINE HYDROCHLORIDE ANHYDROUS 20 mg/mL; LIDOCAINE HYDROCHLORIDE 10 mg/mL (+1 more)Jul 15, 2026Sep 3, 2026
ProPharma DistributionrepackagerLIDOCAINE HYDROCHLORIDE 20 mg/mL; LIDOCAINE HYDROCHLORIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Sandoz Inc.LIDOCAINE HYDROCHLORIDE 10 mg/mL; LIDOCAINE HYDROCHLORIDE 20 mg/mLSep 3, 2026Sep 3, 2026
Sportpharm LLCLIDOCAINE HYDROCHLORIDE 10 mg/mL; LIDOCAINE HYDROCHLORIDE 20 mg/mL; LIDOCAINE HYDROCHLORIDE ANHYDROUS 20 mg/mLJul 15, 2026Sep 3, 2026
A-S Medication SolutionsrepackagerLIDOCAINE HYDROCHLORIDE 10 mg/mL; LIDOCAINE HYDROCHLORIDE 20 mg/mLJul 15, 2026Sep 2, 2026
Baxter Healthcare CorporationLIDOCAINE HYDROCHLORIDE 4 mg/mL; LIDOCAINE HYDROCHLORIDE 8 mg/mLJul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCrepackagerLIDOCAINE HYDROCHLORIDE 10 mg/mL; LIDOCAINE HYDROCHLORIDE 20 mg/mLJul 15, 2026Sep 2, 2026
Civica, Inc.LIDOCAINE HYDROCHLORIDE 10 mg/mL; LIDOCAINE HYDROCHLORIDE 20 mg/mLJul 15, 2026Sep 2, 2026
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.LIDOCAINE HYDROCHLORIDE 10 mg/mLJul 15, 2026Sep 2, 2026
HF Acquisition Co LLC, DBA HealthFirstrepackagerLIDOCAINE HYDROCHLORIDE 10 mg/mL; LIDOCAINE HYDROCHLORIDE 20 mg/mL; LIDOCAINE HYDROCHLORIDE ANHYDROUS 10 mg/mL (+1 more)Jul 15, 2026Sep 2, 2026
Advanced Rx Pharmacy of Tennessee, LLCrepackagerLIDOCAINE HYDROCHLORIDE 10 mg/mLJul 15, 2026Aug 31, 2026
Avenacy, LLCLIDOCAINE HYDROCHLORIDE 10 mg/mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 15, 2026.

Cite this page

DrugDashboards, "Xylocaine MPF — NDC 63323-0492-37," retrieved September 4, 2026, https://drugdashboards.com/drug/63323049237.

Free to cite with attribution — see how the data is put together.